Immunohistochemistry for Cyclin D1 and hnRNP-K was performed on tissue sections cut from the paraffin blocks at 4μm onto positively charged slides (Superfrost plus, Menzel-Glaser, Germany) and stained on an automated platform the (Dako
Autostainer Link 48) using anti-human hnRNPK and Cyclin D1 monoclonal primary antibodies (Santa Cruz Biotechnology, CA, USA) at 1:100 dilution. Heat induced antigen retrieval was used for 30 min at 97°C in the high-PH EnVision™ FLEX Target Retrieval Solution.
The antigen was localized by the addition of 3,3’diaminobenzidine tetrahydrochloride (DAB) substrate chromogen solution (
Universal Detection Kit, Dako, Denmark). Finally, slides were counterstained with hematoxylin, dehydrated in alcohol and mounted.
For each setting, positive and negative control slides were included. As a negative control, bladder tissue was processed in the above mentioned sequences but the primary antibodies were not added and instead add non-immune immunoglobulin G (IgG; DAKO, Glostrup, Copenhagen, Denmark). Colonic mucosa known to express cyclin D1 used as positive control for cyclin D1. Human prostate cancer tissues were used as positive control for hnRNP-K antibody.
Aboushousha T., Hammam O., Helal N, & Dahshan S.E. (2018). Impact of Cyclin D1 and Heterogeneous Nuclear Ribonucleoprotein-K (HnRNP-K) on Urinary Bladder Carcinogenesis. Asian Pacific Journal of Cancer Prevention : APJCP, 19(2), 513-519.